Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The hi ...

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

ProMIS Neurosciences (PMN) announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN ...

BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

Since then, efforts have focused on trying to find vaccines that can stimulate amyloid-binding antibodies without triggering ... promise that accumulation of beta amyloid is a core pathology ...

ALIA-1758 targets pyroglutamate amyloid beta – in a similar way to Kisunla ... One key factor, however, is that anti-pyroglutamate amyloid antibodies seem to reduce the risk of neuroinflammation ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...